Result of AGM

Cizzle Biotechnology Holdings PLC

28 June 2023

 

28 June 2023

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

Result of AGM

Cizzle Biotechnology, the UK-based diagnostics developer, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a show of hands and were passed.

The proxy votes cast in respect of the resolutions were as follows:

Resolution	For		Against		Votes withheld
	Total votes	%	Total votes	%
1.   To receive the Company's annual report and accounts for the year ended 31 December 2022	89,757,080	97.11	2,672,935	2.89	1,661,693
2.    To approve the Directors' Remuneration Report	88,827,568	96.10	3,602,447	3.90	1,661,693
3.   To re-appoint Allan John Syms as a Director of the Company	88,827,578	96.14	3,568,237	3.86	1,695,893
4.    To re-appoint PKF Littlejohn LLP as auditor of the Company	88,861,778	96.14	3,568,237	3.86	1,661,693
5.    To authorise the Directors to determine the auditor's remuneration	88,861,778	96.14	3,568,237	3.86	1,661,693
6.    Authorises the Directors to allot shares in the Company or to grant rights to subscribe for, or to convert any security into, shares in the Company	88,661,778	95.92	3,768,237	4.08	1,661,693
7.    Authorise the Directors to allot equity securities disapplying pre-emption rights	88,823,568	96.10	3,606,437	3.90	1,661,703
8.    That General Meetings may be called on not less than 14 days' notice	88,861,778	96.14	3,568,237	3.86	1,661,693

Enquiries:

Cizzle Biotechnology Holdings plc	Via IFC Advisory
Allan Syms (Executive Chairman)

Allenby Capital Limited	[phone]
John Depasquale
Alex Brearley

Novum Securities Limited	[phone]
Colin Rowbury Jon Bellis

IFC Advisory Limited	[phone]
Tim Metcalfe	[e-mail]
Florence Chandler

Notes to Editors:

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test for the early detection of lung cancer.  Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues.  Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.

For more information, please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

 

END